Alnylam Pharmaceuticals, Inc. $ALNY Shares Newly Acquired by Sanders Morris Harris LLC

Sanders Morris Harris LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,150 shares of the biopharmaceutical company’s stock, valued at approximately $777,000.

Several other institutional investors have also recently added to or reduced their stakes in ALNY. First Citizens Bank & Trust Co. purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $709,000. Krilogy Financial LLC raised its holdings in Alnylam Pharmaceuticals by 80.5% during the third quarter. Krilogy Financial LLC now owns 1,895 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 845 shares in the last quarter. NorthCrest Asset Manangement LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $345,000. Breakwater Capital Group lifted its position in shares of Alnylam Pharmaceuticals by 50.6% during the 3rd quarter. Breakwater Capital Group now owns 1,517 shares of the biopharmaceutical company’s stock worth $374,000 after buying an additional 510 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 38.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,583 shares of the biopharmaceutical company’s stock worth $391,000 after buying an additional 437 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of recent analyst reports. Needham & Company LLC dropped their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $350.00 to $345.00 and set an “outperform” rating on the stock in a research note on Thursday, October 8th. BMO Capital Markets reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Zacks Research raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 5th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $365.50.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $224.47 on Thursday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $30.04 billion, a P/E ratio of 41.72 and a beta of 0.28. The business has a 50 day simple moving average of $238.74 and a 200-day simple moving average of $275.22. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. During the same period in the previous year, the company posted ($0.51) EPS. The company’s quarterly revenue was up 66.9% on a year-over-year basis. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.68 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.